Equities

Jiangsu Cowin Biotech Co Ltd

688426:SHH

Jiangsu Cowin Biotech Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)17.00
  • Today's Change-6.04 / -26.22%
  • Shares traded1.23m
  • 1 Year change-43.67%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments9841,434361
Total Receivables, Net6213239
Total Inventory325333
Prepaid expenses7.167.895.51
Other current assets, total0.01----
Total current assets1,0851,627438
Property, plant & equipment, net395260160
Goodwill, net--4.27--
Intangibles, net302930
Long term investments257----
Note receivable - long term------
Other long term assets--5.411.58
Total assets1,8221,955649
LIABILITIES
Accounts payable484418
Accrued expenses172216
Notes payable/short-term debt000
Current portion long-term debt/capital leases149.055.67
Other current liabilities, total6.861821
Total current liabilities859360
Total long term debt193234
Total debt334140
Deferred income tax8.329.100.06
Minority interest1611--
Other liabilities, total30305.71
Total liabilities159175101
SHAREHOLDERS EQUITY
Common stock1129470
Additional paid-in capital1,3911,393344
Retained earnings (accumulated deficit)160293134
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.300.270.07
Total equity1,6641,780548
Total liabilities & shareholders' equity1,8221,955649
Total common shares outstanding112112112
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.